Related Experiment Video

Updated: May 13, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Inhibiting proliferation of gefitinib-resistant, non-small cell lung cancer

Makoto Sudo1, Tan Min Chin, Seiichi Mori

  • 1Cancer Science Institute, National University of Singapore, Singapore, Singapore. makotosudo@live.jp

Cancer Chemotherapy and Pharmacology
|March 22, 2013
PubMed
Abstract

Insights

The combination of 17-DMAG and belinostat effectively inhibits non-small cell lung cancer (NSCLC) cell growth and prevents tumor formation, offering a potential strategy to overcome tyrosine kinase inhibitor (TKI) resistance.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Tyrosine kinase inhibitor (TKI) resistance is a significant challenge in non-small cell lung cancer (NSCLC) treatment.
  • EGFR mutations are key drivers of TKI sensitivity but also lead to resistance.
  • Identifying novel therapeutic agents to overcome TKI resistance is crucial for improving patient outcomes.

Purpose of the Study:

  • To identify agents that can overcome TKI resistance in NSCLC.
  • To evaluate the efficacy of Hsp90 inhibitor (17-DMAG) and histone deacetylase inhibitor (HDACi, belinostat) in TKI-resistant NSCLC models.

Main Methods:

  • Utilized a panel of 12 NSCLC cell lines, including gefitinib-resistant EGFR mutant lines (H1650, H1975).
  • Screened 10 compounds, focusing on 17-DMAG and belinostat for their effects on cellular proliferation (MTT assay).
  • Assessed the impact of these agents and their combination on EGFR and phospho-Akt expression and in vivo tumor formation in a xenograft model.

Main Results:

  • 17-DMAG and belinostat demonstrated significant anti-proliferative effects across most NSCLC lines.
  • Belinostat reduced EGFR and phospho-Akt expression.
  • The combination of 17-DMAG and belinostat synergistically inhibited proliferation and prevented TKI-resistant tumor formation in vivo.

Conclusions:

  • The combination of 17-DMAG and belinostat shows promise for overcoming TKI resistance in NSCLC.
  • Further clinical investigation of this combination therapy is warranted for TKI-resistant NSCLC patients.

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...